Outreach to Cirrhosis Patients Doubles Screening Rates for Liver Cancer

Cirrhosis (liver disease) patients are at high risk to develop liver cancer, which is increasing in frequency an average of 3% annually and has a five-year overall survival rate of just 17.5%.

Proactive outreach to cirrhosis patients in a safety net health system successfully doubled their screening rates for liver cancer, revealed UT Southwestern Medical Center researchers.

Fibroscan for Fatty Liver Cirrhosis and Fibrosis - Causes, Symptoms, Treatment
Recently, Fibroscan has incorporated the noninvasive Controlled Attenuation Parameter technique to estimate the degree of fatty infiltration in the liver.

‘A proactive, population health outreach strategy can improve liver cancer screening and early detection among cirrhosis patients.’

Tweet it Now

"Finding ways to reach patients at high risk of liver cancer is critical. Liver cancer has the fastest increasing mortality rate among solid tumors in the U.S.," said first author Dr. Amit G. Singal, Associate Professor of Internal Medicine and Clinical Sciences, and a member of the Harold C. Simmons Comprehensive Cancer Center. "This high mortality is primarily due to low rates of liver cancer screening and high rates of late-stage diagnosis."

The study randomly divided 1,800 cirrhosis patients at Parkland Health & Hospital System in Dallas into three groups. The first group received mailed outreach invitations for screening ultrasound. The second group received similar outreach plus patient navigation, and the third received their usual care. Researchers learned that the group receiving mailed outreach invitations were most likely to schedule an ultrasound, which doubled the overall rate of screening.

The study appears in the journal Gastroenterology.

Converting Cirrhosis-Causing Cells to Healthy Liver Cells in Mice
It could soon be possible to generate healthy new liver cells within the organ itself, making engraftment unnecessary, suggested mice studies.

"Our study is one of the first interventions to improve liver cancer screening and early detection among at-risk patients. The vulnerable patient population we studied in our safety net health system are those who are at highest risk of dying from liver cancer, so this intervention helped those who might benefit the most," said Dr. Singal.

Only one-fourth of patients with cirrhosis in routine care are currently screened every six months for liver cancer with an ultrasound as recommended by national guidelines. Symptoms are not usually present when the cancer is in its early stages.

Research: Hundreds of People Developing Alcohol-related Cirrhosis Could Be Prevented Using 'Traffic Light' Test
Harmful drinking rates could be reduced by a simple 'traffic light' test that detects hidden liver fibrosis and cirrhosis in high risk populations.

"Our research previously demonstrated that liver cancer screening is underused in clinical practice, with lower rates of screening among racial/ethnic minorities and socioeconomically disadvantaged patients," said senior author Dr. Ethan Halm, Director of the Center for Patient-Centered Outcomes Research, Chief of the William T. and Gay F. Solomon Division of General Internal Medicine, and Professor of Internal Medicine and Clinical Sciences. "Our new study presents a model of a proactive, population health outreach strategy that can improve liver cancer screening and early detection among those at highest risk of adverse outcomes." Dr. Halm holds the Walter Family Distinguished Chair in Internal Medicine in Honor of Albert D. Roberts.

According to the National Cancer Institute, liver cancer is diagnosed in an estimated 39,230 people annually. In 2013, there were an estimated 54,954 people living with this cancer in the U.S. Risk factors include a diagnosis of fatty liver disease, hepatitis B, hepatitis C, cirrhosis, or a combination of these diseases.

Analyzing Mouth Bacteria can Predict Hospitalizations in Liver Cirrhosis Patients
The study suggests that there may be a change in the overall mucosal-immune interface in cirrhosis patients, with a more toxic microbiota in gut and oral cavity.

Source-Eurekalert